Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell
Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell
Edgewise的Sevasemten治療貝克肌營養不良症的第二階段試驗達成主要終點；股價在開盤前上漲22%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間